Oncosec Medical Inc (ONCS) 0.2325 $ONCS
OncoSec Medical and Massachusetts General Hospital to Evaluate Efficacy of Intratumoral Delivery of DNA-Based Interleukin-12
PR Newswire - Mon May 18, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it has entered a Sponsored Research Agreement (SRA) with Massachusetts General Hospital, an affiliate of Harvard Medical School. Under the agreement, researchers will evaluate the immunologic mechanisms underlying the anti-tumor effects of OncoSec's clinical stage platform, ImmunoPulseTM IL-12, in a Human Papilloma Virus (HPV) tumor mouse model. HPV-associated tumors include oropharyngeal and certain genitourinary cancers (e.g., cervical cancer).
OncoSec Medical Announces FINRA Approval of Reverse Stock Split
PR Newswire - Fri May 15, 3:01PM CDT
OncoSec Medical Inc. ("OncoSec" (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Financial Industry Regulatory Authority ("FINRA" has approved the company's 1-for-20 reverse stock split. According to FINRA's approval, the reverse stock split will become effective and OncoSec's common stock will begin trading on a post-split basis before the open of trading on May 18, 2015.
Penny Stocks Research for Hangover Joe's, OncoSec Medical, Medical Marijuana, TOTALLY HEMP CRAZY, EKSO BIONICS, and Valmie Resources
PR Newswire - Fri May 15, 7:47AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hangover Joe's (OTCMKTS:HJOE), OncoSec Medical (OTCMKTS:ONCS), Medical Marijuana (OTCMKTS:MJNA), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), EKSO BIONICS (OTCBB:EKSO), and Valmie Resources (OTCBB:VMRI).
OncoSec Medical Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
PR Newswire - Thu May 14, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Secretary of State of Nevada on May 18, 2015 and the company's common stock will begin trading on a split-adjusted basis upon Financial Industry Regulatory Authority (FINRA) approval.
Vista Partners Publishes May 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed May 13, 8:01AM CDT
Vista Partners ("Vista" has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
VUZI: 5.80 (+0.22), QQQ: 110.06 (+0.48)
Robert H. Pierce, MD, Chief Scientific Officer of OncoSec Medical, Invited to Present at 11th Annual PEGS Conference in Boston
PR Newswire - Thu May 07, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, presented preliminary findings indicating that ImmunoPulse(TM) IL-12 can increase tumor infiltrating lymphocytes (TILs) in patients with Merkel cell carcinoma and melanoma. ImmunoPulse(TM) IL-12, which employs intratumoral electroporation to enhance delivery of DNA-based interleukin-12 (IL-12), is designed to promote anti-tumor activity. These interim findings are consistent with preclinical data and support a rationale for combining ImmunoPulse(TM) IL-12 with anti-PD-1 and other checkpoint therapies.
Vista Partners Updates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20
Marketwired - Wed May 06, 8:01AM CDT
Vista Partners announced today that it has updated coverage on OncoSec Medical Inc. (OTCQB: ONCS) ("the Company" , a biopharmaceutical company developing DNA-based intratumoral cancer immunotherapies based in San Diego, CA, and maintains its twelve month price target of $1.20. Ross Silver, Principal Analyst at Vista Partners, stated, "There seems to be growing anticipation to learn when and if immunotherapy may become the standard of care for the treatment of certain types of cancer and potentially all types of cancer in the future. On April 29th, 2015, the FDA's panel made a ruling on Amgen's (AMGN) dual-acting cancer vaccine/viral therapy, talimogene laherparepvec (T-Vec) with a convincing 22-1 committee approval. Amgen is a one of the larger holdings in the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). After T-Vec's recent success and with what seems to be a growing trend in immunotherapy, one which is leaning towards utilizing electroporation based on the data ONCS has produced to date, the projected market value for Melanoma therapeutics is anticipated to reach $3.6 billion by 2020 according to MarketWatch." Mr. Silver concludes, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF) in November, to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. According to ONCS, recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. According to ONCS, patients are expected to be enrolled within the next 60 days and enrollment is scheduled to be completed within 12 months."
MRK: 60.01 (-0.22), IBB: 360.30 (+4.69), AMGN: 163.44 (+1.08)
OncoSec Medical to Present at Prominent Scientific and Investment Conferences in May
PR Newswire - Mon May 04, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that leadership members will present at several high-profile events in May, including: PEGS - The Essential Protein Engineering Summit, 2015 Marcum MicroCap Conference, and Sachs Immuno-Oncology: Business Development & Licensing (BD&L) and Investment Forum.
T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences
CNW Group - Fri Apr 24, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company" , a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR" , is pleased to announce that it, together with certain of its shareholders, has closed the transaction announced on March 11, 2015 with Medna Biosciences Inc. ("Medna" . Medna has acquired (the "Escrow Transfer" a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares have been transferred within the escrow and remain bound by those terms and conditions. The Escrow Transfer has been approved by the TSX Venture Exchange.
TPI.VN: 0.415 (-0.025)
Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 5.75 (-0.02), BLCM: 22.18 (-0.84), KITE: 46.39 (-3.63), PFE: 33.98 (-0.01), MRK: 60.01 (-0.22), CLLS: 31.70 (-0.55), SPPI: 6.56 (-0.12), JUNO: 40.81 (-2.56), BMY: 68.00 (+0.36)
Vista Partners Publishes April 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed Apr 08, 7:01AM CDT
Vista Partners ("Vista" has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
VUZI: 5.80 (+0.22), SYRX: 1.93 (+0.05)
Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 103.42 (+1.12), CYCC: 0.77 (-0.04), NVS: 104.06 (+0.31), KPTI: 27.02 (+2.21)
OncoSec Medical to Present at Needham & Company's 14th Annual Healthcare Conference
Business Wire - Thu Apr 02, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at Needham & Company's 14th Annual Healthcare Conference on Tuesday, April 14, 2015 in New York City. The presentation is scheduled to begin at 8:40 AM ET at the Westin Grand Central Hotel.
Sezary Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k76vbh/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Sezary Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - Merck & Co., Inc. - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - OncoSec Medical Inc. - Janssen Global Services, LLC - Emergent BioSolutions Inc. - arGEN-X BV - Angimmune LLC For more information visit http://www.researchandmarkets.com/research/k7...y_syndrome
EBS: 30.91 (+0.19), MRK: 60.01 (-0.22)
Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"
PR Newswire - Mon Mar 30, 5:33PM CDT
TapImmune Inc. (OTCQB: TPIV), wishes to provide clarification on its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City on March 26. TapImmune was represented at this meeting by Dr. Glynn Wilson, Chairman & CEO of TapImmune and Dr. John Bonfiglio, Strategic Advisor to the Company. Regrettably, due to parallel meeting sessions running behind schedule, Dr. Wilson was unable to present a webcast at 4:30pm Eastern Time as originally scheduled in order to participate as an invited panellist in an important discussion on "What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapies?" Other panellists were Dr. Robert Stein, CSO of Agenus, Inc., Dr. Reiner Laus, CEO of Annias Immunotherapeutics, Dr. Robert Pierce, CMO of OncoSec Medical, and David Berd, CMO of AVAX Technologies. The panel discussion was moderated by Dr. Mac Cheever, MD, Fred Hutchinson Cancer Research Center, who also served as the Keynote speaker at the conference.
OncoSec Medical Has A Promising Technology
Clinically Sound Investor - at Seeking Alpha - Mon Mar 30, 8:18AM CDT
MRK: 60.01 (-0.22), BMY: 68.00 (+0.36)
OncoSec Medical CEO Punit Dhillon to Host Live Webinar to Provide Corporate Update and 2015 Outlook
Business Wire - Tue Mar 17, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it will provide a comprehensive corporate update and Q&A session for investors and the general public during a webinar starting at 9:30 AM PDT on Monday, March 23, 2015.
Penny Stocks Alerts for Perk International, MySkin, OncoSec Medical, Data Storage, Relmada Therapeutics, and Allied Nevada Gold
PR Newswire - Fri Mar 13, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Perk International (OTCBB
RKI), MySkin (OTCBB:CNAB), OncoSec Medical (OTCMKTS:ONCS), Data Storage (OTCMKTS
TST), Relmada Therapeutics (OTCMKTS:RLMD), and Allied Nevada Gold (OTCMKTS:ANVGQ).
OncoSec Medical Announces Six Months Results for Fiscal Year End 2015
Business Wire - Thu Mar 12, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec" (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the six months ended January 31, 2015.
T-Bird Pharma Inc. Announces Partnership with Medna Biosciences Inc.
CNW Group - Wed Mar 11, 3:15PM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company" , a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR" , is pleased to announce that it, together with certain of its shareholders, has entered into an agreement with Medna Biosciences Inc. ("Medna" whereby Medna will acquire (the "Escrow Transfer" a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares will be transferred within escrow and remain bound by those terms and conditions. The Escrow Transfer is subject to TSX-V approval.
INO: 8.11 (+0.14), TPI.VN: 0.415 (-0.025)
OncoSec Medical and Massachusetts General Hospital to Evaluate Efficacy of Intratumoral Delivery of DNA-Based Interleukin-12
PR Newswire - Mon May 18, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it has entered a Sponsored Research Agreement (SRA) with Massachusetts General Hospital, an affiliate of Harvard Medical School. Under the agreement, researchers will evaluate the immunologic mechanisms underlying the anti-tumor effects of OncoSec's clinical stage platform, ImmunoPulseTM IL-12, in a Human Papilloma Virus (HPV) tumor mouse model. HPV-associated tumors include oropharyngeal and certain genitourinary cancers (e.g., cervical cancer). OncoSec Medical Announces FINRA Approval of Reverse Stock Split
PR Newswire - Fri May 15, 3:01PM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Financial Industry Regulatory Authority ("FINRA" has approved the company's 1-for-20 reverse stock split. According to FINRA's approval, the reverse stock split will become effective and OncoSec's common stock will begin trading on a post-split basis before the open of trading on May 18, 2015. Penny Stocks Research for Hangover Joe's, OncoSec Medical, Medical Marijuana, TOTALLY HEMP CRAZY, EKSO BIONICS, and Valmie Resources
PR Newswire - Fri May 15, 7:47AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hangover Joe's (OTCMKTS:HJOE), OncoSec Medical (OTCMKTS:ONCS), Medical Marijuana (OTCMKTS:MJNA), TOTALLY HEMP CRAZY (OTCMKTS:THCZ), EKSO BIONICS (OTCBB:EKSO), and Valmie Resources (OTCBB:VMRI).
OncoSec Medical Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
PR Newswire - Thu May 14, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Secretary of State of Nevada on May 18, 2015 and the company's common stock will begin trading on a split-adjusted basis upon Financial Industry Regulatory Authority (FINRA) approval. Vista Partners Publishes May 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed May 13, 8:01AM CDT
Vista Partners ("Vista"
has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of May. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. VUZI: 5.80 (+0.22), QQQ: 110.06 (+0.48)
Robert H. Pierce, MD, Chief Scientific Officer of OncoSec Medical, Invited to Present at 11th Annual PEGS Conference in Boston
PR Newswire - Thu May 07, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, presented preliminary findings indicating that ImmunoPulse(TM) IL-12 can increase tumor infiltrating lymphocytes (TILs) in patients with Merkel cell carcinoma and melanoma. ImmunoPulse(TM) IL-12, which employs intratumoral electroporation to enhance delivery of DNA-based interleukin-12 (IL-12), is designed to promote anti-tumor activity. These interim findings are consistent with preclinical data and support a rationale for combining ImmunoPulse(TM) IL-12 with anti-PD-1 and other checkpoint therapies. Vista Partners Updates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20
Marketwired - Wed May 06, 8:01AM CDT
Vista Partners announced today that it has updated coverage on OncoSec Medical Inc. (OTCQB: ONCS) ("the Company"
, a biopharmaceutical company developing DNA-based intratumoral cancer immunotherapies based in San Diego, CA, and maintains its twelve month price target of $1.20. Ross Silver, Principal Analyst at Vista Partners, stated, "There seems to be growing anticipation to learn when and if immunotherapy may become the standard of care for the treatment of certain types of cancer and potentially all types of cancer in the future. On April 29th, 2015, the FDA's panel made a ruling on Amgen's (AMGN) dual-acting cancer vaccine/viral therapy, talimogene laherparepvec (T-Vec) with a convincing 22-1 committee approval. Amgen is a one of the larger holdings in the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). After T-Vec's recent success and with what seems to be a growing trend in immunotherapy, one which is leaning towards utilizing electroporation based on the data ONCS has produced to date, the projected market value for Melanoma therapeutics is anticipated to reach $3.6 billion by 2020 according to MarketWatch." Mr. Silver concludes, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF) in November, to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA(R) (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. According to ONCS, recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. According to ONCS, patients are expected to be enrolled within the next 60 days and enrollment is scheduled to be completed within 12 months." MRK: 60.01 (-0.22), IBB: 360.30 (+4.69), AMGN: 163.44 (+1.08)
OncoSec Medical to Present at Prominent Scientific and Investment Conferences in May
PR Newswire - Mon May 04, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that leadership members will present at several high-profile events in May, including: PEGS - The Essential Protein Engineering Summit, 2015 Marcum MicroCap Conference, and Sachs Immuno-Oncology: Business Development & Licensing (BD&L) and Investment Forum. T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences
CNW Group - Fri Apr 24, 7:00AM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR" , is pleased to announce that it, together with certain of its shareholders, has closed the transaction announced on March 11, 2015 with Medna Biosciences Inc. ("Medna" . Medna has acquired (the "Escrow Transfer" a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares have been transferred within the escrow and remain bound by those terms and conditions. The Escrow Transfer has been approved by the TSX Venture Exchange. TPI.VN: 0.415 (-0.025)
Heat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
Sharon di Stefano - Seeking Alpha - Tue Apr 14, 8:20AM CDT
Vaccination, in medical terminology, is injection of a disease-causing microorganism that stimulates the immune system to fight against infection, using the body's own defense mechanisms. Vaccination has all but wiped out polio, tetanus, chicken pox...
HTBX: 5.75 (-0.02), BLCM: 22.18 (-0.84), KITE: 46.39 (-3.63), PFE: 33.98 (-0.01), MRK: 60.01 (-0.22), CLLS: 31.70 (-0.55), SPPI: 6.56 (-0.12), JUNO: 40.81 (-2.56), BMY: 68.00 (+0.36)
Vista Partners Publishes April 2015 Macroeconomic & Investment Newsletter
Marketwired - Wed Apr 08, 7:01AM CDT
Vista Partners ("Vista"
has published its FREE Macroeconomic & Investment Monthly Newsletter for the month of April. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. VUZI: 5.80 (+0.22), SYRX: 1.93 (+0.05)
Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 07, 11:05AM CDT
The report "Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-cell lymphomas (CTCLs) are a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques and tumors. Cutaneous T cell lymphoma (CTCL) has four stages of progression: patch stage, plaque stage, tumor stage, and erythroderma stage. The disease can manifest at any stage and does not necessarily go through an orderly progression. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/cutaneous-t-...eport.html
JNJ: 103.42 (+1.12), CYCC: 0.77 (-0.04), NVS: 104.06 (+0.31), KPTI: 27.02 (+2.21)
OncoSec Medical to Present at Needham & Company's 14th Annual Healthcare Conference
Business Wire - Thu Apr 02, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at Needham & Company's 14th Annual Healthcare Conference on Tuesday, April 14, 2015 in New York City. The presentation is scheduled to begin at 8:40 AM ET at the Westin Grand Central Hotel. Sezary Syndrome Global Clinical Trials Review, H1, 2015
M2 - Wed Apr 01, 6:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k76vbh/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. Sezary Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Sezary Syndrome Therapeutics Clinical Trials - Eisai Co., Ltd. - Merck & Co., Inc. - Shionogi & Co., Ltd. - Kirin Holdings Company, Limited - OncoSec Medical Inc. - Janssen Global Services, LLC - Emergent BioSolutions Inc. - arGEN-X BV - Angimmune LLC For more information visit http://www.researchandmarkets.com/research/k7...y_syndrome
EBS: 30.91 (+0.19), MRK: 60.01 (-0.22)
Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"
PR Newswire - Mon Mar 30, 5:33PM CDT
TapImmune Inc. (OTCQB: TPIV), wishes to provide clarification on its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City on March 26. TapImmune was represented at this meeting by Dr. Glynn Wilson, Chairman & CEO of TapImmune and Dr. John Bonfiglio, Strategic Advisor to the Company. Regrettably, due to parallel meeting sessions running behind schedule, Dr. Wilson was unable to present a webcast at 4:30pm Eastern Time as originally scheduled in order to participate as an invited panellist in an important discussion on "What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapies?" Other panellists were Dr. Robert Stein, CSO of Agenus, Inc., Dr. Reiner Laus, CEO of Annias Immunotherapeutics, Dr. Robert Pierce, CMO of OncoSec Medical, and David Berd, CMO of AVAX Technologies. The panel discussion was moderated by Dr. Mac Cheever, MD, Fred Hutchinson Cancer Research Center, who also served as the Keynote speaker at the conference.
OncoSec Medical Has A Promising Technology
Clinically Sound Investor - at Seeking Alpha - Mon Mar 30, 8:18AM CDT
MRK: 60.01 (-0.22), BMY: 68.00 (+0.36)
OncoSec Medical CEO Punit Dhillon to Host Live Webinar to Provide Corporate Update and 2015 Outlook
Business Wire - Tue Mar 17, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced it will provide a comprehensive corporate update and Q&A session for investors and the general public during a webinar starting at 9:30 AM PDT on Monday, March 23, 2015. Penny Stocks Alerts for Perk International, MySkin, OncoSec Medical, Data Storage, Relmada Therapeutics, and Allied Nevada Gold
PR Newswire - Fri Mar 13, 7:45AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Perk International (OTCBB
RKI), MySkin (OTCBB:CNAB), OncoSec Medical (OTCMKTS:ONCS), Data Storage (OTCMKTS TST), Relmada Therapeutics (OTCMKTS:RLMD), and Allied Nevada Gold (OTCMKTS:ANVGQ). OncoSec Medical Announces Six Months Results for Fiscal Year End 2015
Business Wire - Thu Mar 12, 5:00AM CDT
OncoSec Medical Inc. ("OncoSec"
(OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the six months ended January 31, 2015. T-Bird Pharma Inc. Announces Partnership with Medna Biosciences Inc.
CNW Group - Wed Mar 11, 3:15PM CDT
T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"
, a pharmaceutical company focused on developing premium quality medical marijuana products and a licensed producer ("LP" to cultivate marijuana under the Marihuana for Medical Purposes Regulations (Canada) ("MMPR" , is pleased to announce that it, together with certain of its shareholders, has entered into an agreement with Medna Biosciences Inc. ("Medna" whereby Medna will acquire (the "Escrow Transfer" a total of 20,156,790 common shares of T-Bird (45% of the Company's issued shares) from five of its founding shareholders, including its former CEO and CFO, at a price of $0.21 per share. This block of shares is currently held in escrow and the shares will be transferred within escrow and remain bound by those terms and conditions. The Escrow Transfer is subject to TSX-V approval. INO: 8.11 (+0.14), TPI.VN: 0.415 (-0.025)
